Understand the source comparison
SS-LUP-332 Endurance vs AMPK Activators vs Erythropoiesis Stimulators: Mechanism Comparison
SS-LUP-332 (PPARδ agonist) Nuclear receptor activation → mitochondrial biogenesis + fat oxidation shift 14–28 days (transcriptional lag) PPARδ in skeletal muscle nuclei 50–70% endurance increase in preclinical models Best for athletes prioritising oxidative ca
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-LUP-332 (PPARδ agonist)
- Nuclear receptor activation → mitochondrial biogenesis + fat oxidation shift
- 14–28 days (transcriptional lag)
- PPARδ in skeletal muscle nuclei
- 50–70% endurance increase in preclinical models
- Best for athletes prioritising oxidative capacity without glycogen depletion. Requires multi-week commitment
- AMPK activators (e.g., AICAR, metformin)
- Energy-sensor kinase activation → acute glucose uptake + mitochondrial function
- 3–7 days (metabolic signalling)
- AMPK in muscle cytoplasm
- 15–25% endurance gain, dose-limited by GI side effects
- Faster onset but lower ceiling. Practical for short-term metabolic stress adaptation
- Erythropoiesis stimulators (EPO, analogs)
- Red blood cell production → oxygen-carrying capacity
- 10–14 days (erythropoiesis cycle)
- Bone marrow erythroid progenitors
- 8–12% VO2max improvement
- Mechanism is oxygen delivery, not substrate metabolism. Combines well with PPARδ but different pathway
- Beta-alanine (carnosine precursor)
- Intramuscular buffering of hydrogen ions
- 21–28 days (tissue saturation)
- Sarcoplasmic carnosine stores
- 2–5% performance gain in 60–240s efforts
- Targets anaerobic buffering, not oxidative endurance. Minimal overlap with PPARδ mechanisms
- The bottom line: SS-LUP-332 operates upstream of metabolic signalling. It rewrites which genes are transcribed, not just which enzymes are active right now. That's why the timeline is longer and why skipping doses during the first three weeks eliminates efficacy entirely.